Seriously ill patients will have greater and easier access to unapproved medicines due to new USFDA regulations. The new rules establish who is eligible for these new experimental drugs and when manufacturers can charge for them. The FDA predicts a 50% increase in individual applications, and a 25-50% increase in applications from groups of patients. It is also hoped these new rules will encourage companies to provide experimental medicines outside of clinical trials.

For more information, please see: http://www.alertnet.org/thenews/newsdesk/N12141146.htm